Lack of Cumulative @entity137 Associated With XXXX Use in @entity263 .

@entity1 @entity137 @entity263 @entity417 @entity229 @entity16 @entity2664 @entity1398 @entity15513 @entity1205 @entity72837
@entity15513 provided a survival advantage compared with @entity2664 in @entity1 with castration-resistant @entity263 refractory to @entity1205 . Grade 3 to 4 (G3-4) @entity1398 and @entity1398 were relatively frequent in the registrative @entity72837 Plus @entity229 Compared to @entity2664 Plus @entity229 in Hormone Refractory Metastatic @entity263 (TROPIC) trial, but their incidence was lower in the Expanded Access Program (EAP). Although cumulative doses of @entity1205 are associated with @entity16 , the effect of cumulative doses of @entity15513 is unknown. In this retrospective review of prospectively collected data, the authors assessed "per cycle" incidence and predictors of @entity137 in the Italian cohort of the EAP, with a focus on the effect of cumulative doses of @entity15513 .The study population consisted of 218 Italian @entity1 enrolled in the @entity15513 EAP. The influence of selected variables on the most relevant adverse events identified was assessed using a Generalized Estimating Equations model at univariate and multivariate analysis."Per cycle" incidence of G 3 to 4 @entity1398 was 8.7%, whereas @entity1398 was reported in 0.9% of cycles. All events of @entity1398 occurred during the first 3 cycles. Multivariate logistic regression analysis showed that higher prior dose of @entity15513 was associated with decreased odds of having G3 to 4 @entity1398 (OR=0.90; 95% CI: 0.86-0.93; P<0.01), @entity1398 (OR=0.52; 95% CI: 0.34-0.81; P<0.01) and G3 to 4 @entity417 (OR=0.93; 95% CI: 0.86-1; P=0.07). @entity1 with a body surface area >2m presented increased odds of having G 3 to 4 @entity1398 (OR=0.93; 95% CI: 0.86-1; P=0.07), but decreased odds of having G3 to 4 @entity417 .Among the @entity137 assessed, the authors did not identify any that appeared to be associated with a higher number of @entity15513 cycles delivered. Prior cumulative dose was associated with reduced G3 to 4 @entity1398 and @entity417 . The apparent protective effect associated with higher doses of @entity15513 is likely to be affected by early dose reduction and early @entity137 -related treatment discontinuation. Because this analysis is limited by its retrospective design, prospective trials are required to assess the optimal duration of @entity15513 treatment.
